Frontline Hodgkin Lymphoma Trial

ECHELON-1, Study ID: C25003


This trial is currently enrolling patients in the following locations:

Alabama

  • Birmingham

California

  • Duarte
  • Fullerton
  • La Jolla
  • Los Angeles
  • Sacramento
  • San Luis Obispo
  • Santa Monica
  • Stanford

District of Columbia

  • Washington

Florida

  • Fort Myers
  • Jacksonville
  • Miami
  • Orlando

Illinois

  • Chicago
  • Maywood
  • Niles
  • Zion

Indiana

  • Goshen
  • Indianapolis

Iowa

  • Iowa City

Kansas

  • Fairway

Maryland

  • Baltimore
  • Bethesda

Massachusetts

  • Boston

Michigan

  • Ann Arbor
  • Detroit

Minnesota

  • Minneapolis
  • Rochester

Missouri

  • Springfield
  • St. Louis

Nebraska

  • Omaha

Nevada

  • Las Vegas

New Jersey

  • Hackensack
  • Morristown

New Mexico

  • Albuquerque

New York

  • Albany
  • Bronx
  • Commack
  • New York
  • Rochester
  • Rockville Centre

North Carolina

  • Charlotte
  • Raleigh

Ohio

  • Cincinnati
  • Columbus

Oregon

  • Eugene

Pennsylvania

  • Hershey
  • Philadelphia

South Carolina

  • Charleston
  • Greenville

Tennessee

  • Chattanooga
  • Nashville

Texas

  • Austin
  • Dallas
  • Houston
  • San Antonio
  • Tyler

Utah

  • Salt Lake City

Virginia

  • Fairfax

Washington

  • Kennewick
  • Seattle
  • Yakima

West Virginia

  • Morgantown

Wisconsin

  • Milwaukee

Australia

  • Bedford Park
  • East Melbourne
  • Geelong
  • Heidelberg
  • Hobart
  • Kingswood
  • Parkville
  • Perth
  • South Brisbane
  • St. Leonards
  • Westmead

Belgium

  • Antwerpen
  • Brugge
  • Gent

Brazil

  • Salvador
  • Rio De Janeiro
  • Sao Paulo

Canada

  • Edmonton
  • Halifax
  • Montreal
  • Toronto
  • Vancouver
  • Winnipeg

Czech Republic

  • Hradec Kralove
  • Prague
  • Praha 10

Denmark

  • Aalborg
  • Aarhus
  • Copenhagen
  • Herlev
  • Odense
  • Roskilde

France

  • La Tronche
  • Limoges

Hungary

  • Budapest
  • Debrecen
  • Pécs
  • Szeged
  • Szolnok

Italy

  • Alessandria
  • Bologna
  • Cagliari
  • Cuneo
  • Genova
  • Milano
  • Modena
  • Napoli
  • Rionero in Volture
  • Rozzano Milano
  • Rome
  • Rozzano
  • Torrette di Ancona

Japan

  • Fukuoka
  • Hiroshima
  • Isehara-shi
  • Maebashi
  • Nagoya
  • Osaka
  • Sendai

Republic of Korea

  • Busan
  • Daegu
  • Goyang
  • Incheon
  • Seoul

Norway

  • Oslo

Poland

  • Gdansk
  • Katowice
  • Krakow
  • Lódz
  • Olsztyn
  • Warszawa

South Africa

  • Johannesburg

Spain

  • Badalona
  • Barcelona
  • Marbella
  • Pamplona
  • Salamanca
  • Snatiago de Compostela
  • Valencia

Taiwan

  • Changhua City
  • Chiayi County
  • Tainan
  • Taipei
  • Taoyuan County

Turkey

  • Ankara
  • Istanbul
  • Samsun

United Kingdom

  • Aberdeen
  • Birmingham
  • Canterbury
  • Cardiff
  • Exeter
  • Glasgow
  • Inverness
  • Leicester
  • Lincoln
  • Liverpool
  • London
  • Manchester
  • Norfolk
  • Northwood
  • Nottingham
  • Oxford
  • Romford
  • Southampton
  • Sutton
  • Truro

For more information, please check this trial's clinicaltrials.gov posting, or contact the Millennium Medical and Drug Information Center, 877-674-3784, medical@mlnm.com

Updated March 3, 2015

Study Name

A phase 3 randomized, two-arm trial of brentuximab vedotin plus AVD (doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as front-line therapy in patients with advanced classical Hodgkin lymphoma.

What is a phase 3 study?

A phase III study normally involves more patients than a phase 2 trial and confirms the efficacy of the study drug and compares it to commonly used therapies. They also generate long-term safety data for the study drug.

Who can participate?

  • You are18 years or older with a diagnosis of classical Hodgkin lymphoma.
  • You have not received prior therapy for this disease.
  • At a minimum, you are able to move around and are capable of self-care. You are up and about more than half of waking hours.

Why is the study being done?

This study is being done to test the effectiveness of brentuximab vedotin when given to patients who have had no prior therapy for classical Hodgkin lymphoma. It will compare the study drug's effectiveness in combination with AVD to ABVD.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave SeattleGenetics.com?

No, return to SeattleGenetics.com

Yes, leave SeattleGenetics.com